Janux Therapeutics, Inc. JANX
10.92 USD 0.00 (+0.00%)
Regular-session close
10.92 0.00 0.00%
Pre-market · Nov 17, 9:25 AM ET
Day range unavailable
10.73 52-week range 35.34
- YTD
- -20.87%
- 1 year
- -62.70%
Benzinga news
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…benzinga.com Janux Therapeutics Reports Initial Phase 1 JANX011 Data, Providing Clinical Validation For ARM Platform In Autoimmune Diseases A single 3 mg subcutaneous dose produced greater than 90% peripheral B-cell depletion in most participants, including two participants with B cells below the limit of detection, with B-cell…
benzinga.com Truist Securities Maintains Buy on Janux Therapeutics, Raises Price Target to $27 Truist Securities analyst Supawat Thongthip maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and raises the price target from $26 to $27.
benzinga.com Wedbush Maintains Outperform on Janux Therapeutics, Raises Price Target to $40 Wedbush analyst Robert Driscoll maintains Janux Therapeutics (NASDAQ:JANX) with a Outperform and raises the price target from $36 to $40.
benzinga.com Barclays Maintains Underweight on Janux Therapeutics, Raises Price Target to $15 Barclays analyst Etzer Darout maintains Janux Therapeutics (NASDAQ:JANX) with a Underweight and raises the price target from $14 to $15.
benzinga.com Janux Therapeutics Q3 EPS $(0.34) Beats $(0.46) Estimate, Sales $9.290M Beat $7.746M Estimate Janux Therapeutics (NASDAQ:JANX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.46) by 26.09 percent. This is a 12.82 percent increase over losses of…
